We report on the analysis of a murine anaplastic lymphoid cell line TS1G6, established recently by interleukin (IL)-9 transfection. TS1G6 revealed a highly characteristic pattern of large anaplastic cells with mononuclear, binuclear, or multinuclear cells resembling Hodgkin (H) or Sternberg-Reed (SR) cells. This cell line is tumorigenous after injection of as few as 10 4 lymphoma cells into nude or immunocompetent C57Bl/6 mice and leads to death from progressive disease of all treated animals within a few weeks. The histological analysis of these tumors revealed a diffuse large cell malignant lymphoma that is morphologically almost identical to human anaplastic large cell lymphoma (ALCL). The lymphoma cells did not show overexpression of the anaplastic lymphoma kinase (ALK) gene, which is found in about 50% of the cases of human ALCL. Thus, this model may be an animal model for an important subset of human ALCL. The cytokine profile, which is of the T helper 2 type, showed strong parallels to the human lymphoma counterpart. Mice suffering from such lymphomas could not be cured with a regimen using high dose cyclophosphamide similar to many ALCL patients. Such an animal model for ALCL has not yet been recognized, but may provide the basis for investigating new antitumor immunotherapies in a fully immunocompetent host . (Lab Invest 2000, 80:1523-1531.
A naplastic large cell lymphoma (ALCL) is defined by morphology with the presence of large, anaplastic, sometimes Hodgkin (H)-and Sternberg-Reed (RS)-like cells and sometimes a carcinoma-like growth pattern with intrasinusoidal spreading combined with CD30 expression. The infiltrate is accompanied by a variable admixture of histiocytes, epithelioid cells, neutrophils, eosinophils, lymphocytes, and plasma cells (Lennert and Feller, 1992) . Most cases of human ALCL were shown to be of T-or 0-cell origin, whereas only a minority of cases showed an expression of B-cell differentiation antigens. Moreover, the normal cellular counterpart for anaplastic large cell lymphoma is not yet recognized (Harris et al, 1994 ).
Because there is major interest in defining the lymphomagenesis of ALCL, several groups have tried to establish ALCL-cell lines for many years. However, only a small number of such human cell lines currently exist (Barbey et al, 1990; Dirks et al 1996; Drexler and Minowada, 1992; Drexler, 1993) . Only four in vivo models of ALCL have been reported so far (Kinney et al, 1993; Kuefer et al, 1997; Pasqualucci et al, 1995; Terenzi et al, 1996 ).
An animal model mimicking this kind of human lymphoma can be advantageous for the establishment of new therapeutic strategies. However, it has been shown to be difficult to establish heterotransplants of malignant lymphomas successfully (Kapp et al, 1992) . Moreover, clinical trials on human lymphoma models in immunodeficient mice were hampered by the fact that these animals were devoid of a functional immune system and, thus, artificial with respect to the biology and clinical behavior of the growing tumors. In this study we report the morphology and biology of a murine anaplastic lymphoid cell line, TS1G6, and the respective tumors in syngeneic C57Bl/6 mice, which showed strong parallels to their human counterpart.
Results and Discussion
The study of the biology of ALCL has been hampered by the difficulty of establishing cell lines from such lymphoma. Until now, reports of well-characterized animal models for ALCL had not been published. In this study we describe the progressive in vivo growth of an interleukin (IL)-9 transformed T cell line (TS1G6) in immunocompetent syngeneic mice that developed ALCL-like malignant anaplastic large cell lymphoma.
Morphological and Immunohistochemical Characterization of TS1G6 Cell Line
The murine cell line TS1G6 was reported in detail earlier (Uyttenhove et al, 1991) . In brief, an intraabdominal (IAb)-restricted, CD3ϩ, CD4ϩ T helper cell clone (TS1) derived from a C57Bl/6 mouse and specific for human keyhole limpet hemocyanin (KLH) was cultured without antigen and feeder cells, but in the presence of IL-9. This growth factor-dependent TS1 clone was subsequently transfected with the IL-9 cDNA in the expression vector pBMGneo (using the bovine papilloma virus promoter and neomycin as selection drug). Although the cells transfected with the sense construct no longer required exogenously added IL-9, the cells transfected with the antisensecontrol (IL-9 antisense construct) remained IL-9 dependent. The uncloned transfected cells were subcloned and the clones, TS1G6 and TS1E10 (sense and anti-[mis-]sense respectively), were further tested for tumorigenicity. Although all animals treated with TS1G6 cells showed development of progressive tumors, not a single tumor was obtained after injection of TS1E10 cells. The capacity to form and establish tumors of the cell lines TS1G6/TS1E10 is shown schematically in Figure 1 .
Cytologically the TS1G6 cells showed marked heterogeneity in cell size with diameters ranging from 20 m to 100 m. Many cells were mononuclear, but bior multinucleated (sometimes more than 10 nuclei) cells were frequently found. Much similar to single cells derived from human ALCL, the nuclei have vesicular chromatin with one or several prominent, centrally located, sometimes inclusion-like, eosinophilic nucleoli. The cytoplasm is abundant, vacuolated, and basophilic in Pappenheim staining (Fig. 2, a and b) .
The immunophenotype of the cultured cells analyzed by FACS (fluorescence-activated cell sorting) showed a progressive loss or down-regulation of some antigens like CD3 and CD4 after long term in vitro culture (data not shown) (Renauld et al, 1993) . This can also be observed in human ALCL tumors, where more than 30% of the so-called 0-cell-type show no expression of T-cell antigens at all. However, as in human ALCL (Harris et al, 1994; Louahed et al, 1995) , the activation antigens CD30 and CD25 and the transferrin-receptor CD71 were expressed (Fig. 3, a to  c) . The hallmark antigen for human ALCL, CD30, could be demonstrated on the majority of tumor cells, although weakly. The cDNA-and protein-sequences for human and mouse CD30 differ significantly, and thus the function and expression intensity of CD30, which is not well understood even for the human system, may also differ (Kinney et al, 1993) . In summary, the phenotype is well in accordance with cells derived from human ALCL of the T-cell type (Harris et al, 1994; Louahed et al, 1995) .
Analysis of TCR-Rearrangement
The cloning procedure of the TS1 cells assured that the TS1G6 T-cells were derived from a single cell and thus of clonal nature. This was confirmed by analyzing The cytokine mRNAs for IL-4, IL-5, IL-6, IL-9, and IL-10 were expressed, whereas the mRNAs for IL-2, IL-12, interferon-␥ (IFN-␥), and granulocyte macrophage-colony stimulating factor (GM-CSF) could not be detected. Moreover, the cytokine receptors IL-7R and IL-9R were also expressed (data not shown). This cytokine expression profile displays the typical profile of TH2 cells, because the B-cell stimulating/modulating cytokines IL-4, IL-9, and IL-10 were expressed whereas the TH1 cytokines, IL-2 and interferon-␥, were not detectable (Fiorentino et al, 1989) .
It is supposed that TH2 cytokines are expressed by CD30ϩ, CD4ϩ T-helper cells (Del Prete et al, 1995) . CD30 expression seems to be associated with the differentiation/activation pathway of TH2 cells, and CD30 triggering by CD30 ligand-expressing, antigenpresenting cells may represent an important costimulus for the development of TH2 responses. In contrast, Hamann et al (1996) could not find evidence for discrimination of TH1-and TH2-type T cells by CD30 expression.
Although we have not made an attempt to correlate CD30 expression with TH1-and TH2-type cytokine expression pattern of nonneoplastic T cells in our model, we could clearly show weak CD30 expression and expression of TH2 cytokines in the cell line TS1G6.
It is of interest that this pattern of cytokine expression is found in most, if not all human ALCL and even, at least in part, in many other non-Hodgkin's lymphomas of the T cell type (Boulland et al, 1998; Merz et al, 1991a; Merz et al, 1991b) .
In addition, mRNA for the cytokine receptor IL-9R was also detected. This result was expected because the cloning procedure of the mother cell line TS1 was based on the exogenous addition of IL-9 and its requirement for growth of the cells. Although we do not know whether this pattern of cytokine expression is transferred into protein expression, we suppose that this is the case because bioactive IL-9, for example, could be measured in the supernatant of the cells (measured by the proliferation of IL-9 dependent Mo7E cells; data not shown).
It is tempting to speculate about the suppression of the host immune response, eg, cytotoxic response against the ALCL tumor through expression of TH2 cytokines and subsequent down-regulation of the TH1 "cytotoxic" system. It is worthwhile to study this hypothesis in more detail because new therapeutic 
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Figure 4.
Cytokine profile of the cell line TS1G6 using RT-PCR analysis.
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Analysis of ALK1 Expression by RT-PCR and Northern-blot
Aberrant expression of anaplastic lymphoma kinase (ALK) occurs in 30% to 60% of human anaplastic large cell non-Hodgkin's lymphomas of the T or 0 cell type. By using RT-PCR, we were not able to detect mRNA for the murine homolog of human ALK. As a positive control tissue, mouse brain tissue was used in which we could detect strong expression of murine ALK by using RT-PCR and northern blot analysis. Because approximately 50% of human ALCLs were negative for ALK, the overexpression or aberrant expression of other oncogenes, or the loss of suppressor genes, may also be relevant for the transformation of T lymphocytes into anaplastic lymphoma cells (Falini et al, 1999; Gascoyne et al, 1999) .
Subcutaneous and Disseminated Growth after Injection of TS1G6 Cells into Syngeneic C57Bl/6 Mice
Subcutaneous (sc) or intraperitoneal (ip) injection of cells from the cell line TS1G6 into C57BI/6 mice led to in vivo growth of malignant lymphomas. The sc or ip injection of as few as 10 4 to 10 6 of these transfected TS1G6 cells into syngeneic C57Bl/6 mice resulted in the growth of malignant lymphoma in all animals (100%, 20/20), whereas the TS1E10 cells (transfected with antisense construct) were still dependent on IL-9 in culture and never produced tumors in syngeneic mice nor in immunodeficient nude mice.
Tumors were visible after 9 to 12 days when 10 6 cells were injected, after 12 to 14 days when 10 5 cells were injected, and after 14 to 16 days when 10 4 cells were injected. A typical growth curve of these tumors is shown in Figure 5 .
Signs of progressive disease became visible approximately 4 to 8 weeks after the injection of TS1G6 cells into syngeneic mice. Because the tumors grew slightly faster when cells were injected into nude mice instead of syngeneic mice (Fig. 6) , we suppose that the immune system is able to recognize the tumor cells on the basis of tumor rejection antigens and that T cells are necessary for this recognition and for induction of an antitumor response. Such an antitumor response, which is of little relevance for the velocity of tumor growth or for the outcome of the animals in untreated groups, may be boosted by immunotherapeutic strategies and, thus, may be important for tumor rejection.
Animals developed first local tumors, either in the skin and subcutaneous tissue or in the abdomen, depending on the route of injection. From there, dissemination takes place per continuitatem or via lymphatics. The animals developed malignant lymphomas in nearly all lymph nodes and in the spleen. The axillary, inguinal, cervical, paraaortic, caecal, and renal lymph nodes were involved (Fig. 7) . In addition, extranodal growth was observed in the liver, the kidneys, and the lungs. When animals showed heavy tumor burden (up to 10g total tumor weight), some lymph nodes were about 1 cm in size, and the ratio of total tumor to total body weight was up to 1 to 3, whereas healthy female C57Bl/6 mice weigh approximately 20 to 22g in this age group. Later, the animals often showed tumor cachexia. When the local tumors grew to a considerable size, or when the animals showed signs of distress, they were killed.
There was no evidence of involvement of the bone marrow or thymus. However, because the animals were killed when they suffered from visible tumor burden, we could not exclude that tumors could also spread to these organs.
Histology of the TS1G6 Tumors
Histopathological examinations of the local tumor demonstrated tumors with large, bizarre, anaplastic cells, some of which in part resemble H or SR cells (Fig. 8) . All tumors showed, at least in part, a cohesive growth pattern and were accompanied by a discrete infiltration of neutrophils and/or eosinophils. Some tumors also showed diffuse fibrosis. The cytology of Comparison of tumor growth in nude mice vs syngeneic mice.
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The local skin tumors, as in human ALCL, had a tendency to exulcerate, whereby the tumor cells were arranged in tight tumor nodules infiltrating first the dermis and then the underlying muscles or soft tissues. The local tumors spread per continuitatem, thereby infiltrating the entire abdominal wall and leading to peritoneal dissemination. However, in some animals the nodal and hematogenous dissemination preceded the intraperitoneal dissemination that had resulted from spreading per continuitatem. It is of special interest that the pancreatic gland was frequently infiltrated. This is also sometimes found in human ALCL.
Enlarged lymph nodes showed obliteration of their architecture. Primarily, they had been infiltrated by the tumor cells via the sinuses (Fig. 9a) , leading to subsequent infiltration of the T-zones (Fig. 9b) and finally complete destruction of the lymph node. Hematogenous metastases were found in the vessels of the liver and the lung; some of these vessels were occluded by tumor cell thrombi.
In summary, the tumors show strong parallels, both in their biological behavior and in cytology and histology, to human ALCL. The most important analogies are reviewed in Table 2 .
Treatment with High-Dose Cyclophosphamide
Mice with a local growth of TS1G6 tumors of 0.4 cm in diameter were treated with the chemotherapeutic drug cyclophosphamide (which is used as an important chemotherapeutic drug in the treatment of human ALCLs). A dose of 125 mg cyclophosphamide/kg body weight, equivalent to a high-dose regimen in humans, was injected intraperitoneally and administered as often as six times in intervals as short as 10 days. We have analyzed the blood parameters of the animals after treatment and found complete reconstitution after 7 to 8 days. However, the shortest interval of drug delivery which was able to be tolerated by the animals was 10 days (data not shown). Six out of six mice (100%) did not show significant tumor regression, and all animals developed progressive tumors with little retardation of tumor growth compared to control animals. After increasing the dose to 250 mg/kg body weight (six times after each 10 days), six out of six mice (100%) showed significant delay of tumor growth, and some animals showed macroscopically a short phase of complete remission. However, all animals died of progressive disease (Fig. 10) . Thus, the lymphoma cannot be cured by cyclophosphamide, but it is moderately sensitive to chemotherapy.
It is of particular interest, that chemotherapy, applied even in a high-dose regimen, is able to cure only about one half of human patients.
Thus, ALCL proves to be fatal in many instances, especially in those in which patients primarily present with widespread disease (Kapp et al, 1992; Kuefer et al, 1997; Purtilo et al, 1991) . Therefore, there is a need for animal models for establishing new therapeutical agents or treatment modalities that can cure patients who cannot be cured by already existing therapies and that may be not as harmful as the standard therapies. Until recently, testing of new therapeutic agents, eg, chemo-or immunotherapeutical drugs, has relied extensively upon mice for in vivo preclinical studies (Dick et al, 1991; McCune et al, 1991; Mosier, 1991; Purtilo et al, 1991) . Unfortunately, animal models of malignant lymphomas are rarely reported, and there are only few reports on ALCL (Pasqualucci et al, 1995; Terenzi et al, 1996; Tian et al, 1995) . Furthermore, these animal models do not always mimic the physiological and pathophysiological processes that take place in humans. The failure to cure many patients suffering from ALCL is paralleled by the TS1G6 mouse model.
In summary, we have presented a mouse lymphoma model for a subset of human ALCL (cases without ALK1-expression), which provides the basis for overcoming many of the above-mentioned limitations of conventional therapy and allows further study of the biology and pathogenesis of ALCL in the immunocompetent host. Moreover, it will be interesting to find out whether a TH2 cytokine profile will hold true also in human ALCL. If so, this finding can be used to counterbalance the deranged and biased cytokine milieu as therapeutic strategy using cytokines or anticytokine antibodies. As shown here for the murine model, it is tempting to speculate about autocrine loops in lymphomas that may be disrupted by antisense or anticytokine treatment strategies.
Materials and Methods

In Vitro Culture of the Cell Line TS1G6 and Morphological and Enzyme Histochemical Analysis of Cultured Cells
The cell line TS1G6 was maintained in RPMI 1640 supplemented with 10% heat inactivated fetal calf serum, 2 mmol/L L-glutamine, 50 IU/mL penicillin, and 50 g/mL streptomycin. The cells were cultured in an atmosphere consisting of 5% CO 2 and humidified air.
The cells were prepared for morphological and enzyme-histochemical analysis using ficoll-gradient separation (Ficoll-Hypaque; Pharmacia Biotechnology, Freiburg, Germany) . Cytospin preparations were prepared with 100,000 cells per slide. Slides were stained with Pappenheim (May-Grünwald-Giemsa), hematoxylin-eosin, nonspecific esterase, myeloperoxidase, alkaline phosphatase, Naphthol AS-D chloroacetate esterase, periodic acid-Schiff reaction, and acid phosphatase according to standard histochemical/ enzyme-histochemical procedures. 
Figure 10.
Comparison of the effects on tumor growth of treatments with 125 mg vs 250 mg cyclophosphamide/kg of body weight.
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Flow Cytometric Analysis
The TS1G6 expression of CD30, CD25, CD71, CD3, CD8, and CD4 was evaluated by using the matched murine monoclonal antibody reagents directly conjugated to phycoerythrin (PE) or fluorescein isothiocyanate (FITC) (Pharmingen, Heidelberg, Germany). Cultured Cells were washed with PBS, centrifuged at 400 ϫg for 5 minutes and resuspended at 1 ϫ 10 5 to 1 ϫ 10 6 in 200 l PBS/tube. Cells were incubated using 20 l of PE-or FITC-conjugated anti-mouse antibody reagent including blocking solution (bovine serum albumin, 10 mg/ml; nonconjugated rabbit anti-mouse antibodies, 10 mg/ml) for 20 minutes (in darkness at room temperature) and were washed. After resuspending in 300 l PBS, cells were analyzed within 20 minutes on a FACScan cell analyzer (Becton Dickinson, Heidelberg, Germany) using fluorescence 1 (FL-1) or fluorescence 2 (FL-2) for specific immunolabeling. The Becton Dickinson Cellquest program was used for dual-and single-color analysis respectively. Cell debris were eliminated from the analysis using a gate on forward and sideward scatters. Quadrant markers were set using negative isotype matched controls to define the limits of nonspecific staining.
Northern Blot
Total RNA was isolated from mouse tissues (spleen, lymph-node, liver, and brain) and cell line TS1G6 by the method of Chomczynski and Sacchi (1987) . Poly (A) ϩ -RNA was isolated according to the instructions of the manufacturer (Quiagen, Hilden, Germany). In vitro transcription of DIG-labeled RNA probes was performed using the In Vitro Transkription Kit (Roche, Mannheim, Germany) with the PCR-generated template of mouse ALK. Primer sequences used for cloning of mouse ALK were deduced from the EMBL sequence database (EMBL) as follows: accession number of mouse mRNA for tyrosin kinase (ALK), D83002 (Iwahara et al, 1997) ; ALK-PCR product from position 621 to position 1398; ALK sense primer, 5'ctt cgt tgt acc ctc gct ctt ccg c-3'; and ALK antisense primer, 5'aga atg ctc tgc ctc tgg ccc atc c 3'. Northern blot was carried out using standard methods with a hybridization temperature of 68°C. Chemiluminescent detection of DIG-labeled probes was carried out as described by the manufactures with CDPstar detection (Roche).
Analysis of TCR Rearrangements
Total cellular DNA was prepared from the cell line TS1G6. Pellets of 1ϫ10 6 cells were resuspended in 50 l of proteinase K-buffer (10 mM Tris, pH 8.3, 5 0 mM KCl, 2.5 mM MgCl 2 ) and incubated for 2 hours at 56°C in the presence of proteinase K (100 g/ml). After inactivation of proteinase K, 1 to 5 l (400 ng DNA) of the proceeding suspension were amplified with a Biometra DNA thermal cycler for 35 cycles (40 seconds 95°C, 45 seconds at 55°C, and 1 minute at 72°C) in a volume of 50 l. The reaction mixture included 50 pmol of each primer, 0.2 mM of each dNTP, 50 mM KG, 10 mM Tris-HG (pH 8.3), 1.5 mM MgCl 2 , 0.01% gelatin, and 1.0 U of Taq polymerase (Biometra). Primer pairs used were as follows: V␥l.2: 5'gtgcaaatatcctgta tagtt-3' and J␥2: 5'-acagtagtaggtggcttcac-3'; V␥1.1: Ygagagtgcgcaaatatcctgtata-3' and J␥4:5'-tgggggaatt actacgagct-3'; V␥2/4: 5'tatgtccttgcaacccctac-3' and J␥1: 5'-atgagcttagttccttctgc-3'; V␥5/7: Y-gMatgaagg cccggaca-3' and J␥1; V␥4/6: 5'-acaagtgttcagaag cccga-3' and J␥1; V␥3/5: 5'-tggatatctcaggatcagct-3' and J␥1. Samples (5 l) were electrophoresed in 2% agarose-gel and visualized by ethidium-bromide staining.
Animals
Female 6-to 10-week-old mice of the strain C57Bl/6 were purchased from Charles River Inc. (Sulzfeld, Germany). Five to nine animals were kept in each cage. Animals were exposed to 12 hours light/12 hours dark cycles, and standard food and water were provided as needed.
For studying tumor growth in T cell deficient mice, 6-week-old CD1 nuBR mice, obtained from Charles River Inc. were used. They were kept in isolation under strictly controlled, specific pathogen-free conditions. ), growing exponentially, were injected into the right flank of the mice either subcutaneously or intraperitoneally after having been resuspended in 200 l PBS. The animals were killed when a tumor of more than 1.5 cm in diameter was palpable, or when they presented with a detectable abdominal swelling, or when their health deteriorated.
Establishment of an In
Treatment of Animals
Treatment of tumor-bearing mice with high-dose cyclophosphamide was administered six times in intervals of 10 days, with therapy starting when local growth of TS1G6 tumors was as small as 0.4 cm in diameter. Doses of 125 mg and 250 mg cyclophosphamide/mg body weight were injected intraperitoneally. Cyclophosphamide was a product of ASTA Medica AWD GmbH (Frankfurt, Germany).
Histopathology and Immunhistology of TS1G6 Tumors
The material for microscopic analysis was taken during necropsy after ether anesthesia and cervical dislocation. Skin, lymph node, bone marrow, liver, spleen, and lung tissues were dissected, fixed, paraffin-embedded, and stained for hematoxylineosin, Giemsa's solution, PAS, and Gomori's silver stain according to standard techniques.
